Cancer Consumer Groups Oppose Oncologic Surrogates Citing WHI Experience
Executive Summary
The Women's Health Initiative experience suggests that surrogate endpoints should not be used in oncology, several cancer and consumer advocacy organizations state in a letter to FDA Commissioner McClellan